| Ms Jessica Bridgeford, | |
|
12805 Highway 55 Ste 111, Plymouth, MN 55441-3860 | |
| (763) 520-2222 | |
| Not Available |
| Full Name | Ms Jessica Bridgeford |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 10 Years |
| Location | 12805 Highway 55 Ste 111, Plymouth, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295126084 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | R 182750-9 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthpartners Medical Group | 1759293954 | 1430 |
News Archive
Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary.
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.
Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on August 11, 2011 it filed a 510(k) application with the Food and Drug Administration (FDA) for clearance of its hemodiafiltration system.
› Verified 4 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary.
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.
Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on August 11, 2011 it filed a 510(k) application with the Food and Drug Administration (FDA) for clearance of its hemodiafiltration system.
› Verified 4 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary.
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.
Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on August 11, 2011 it filed a 510(k) application with the Food and Drug Administration (FDA) for clearance of its hemodiafiltration system.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Jessica Bridgeford, 2935 128th Ln Ne, Blaine, MN 55449-7539 Ph: (612) 414-2125 | Ms Jessica Bridgeford, 12805 Highway 55 Ste 111, Plymouth, MN 55441-3860 Ph: (763) 520-2222 |
News Archive
Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary.
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.
Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on August 11, 2011 it filed a 510(k) application with the Food and Drug Administration (FDA) for clearance of its hemodiafiltration system.
› Verified 4 days ago